Shares of StageZero Life Sciences Ltd. (OTCMKTS:GNWSF – Get Free Report) rose 31% during mid-day trading on Wednesday . The company traded as high as $0.12 and last traded at $0.12. Approximately 28,487 shares traded hands during trading, an increase of 7% from the average daily volume of 26,719 shares. The stock had previously closed at $0.09.
StageZero Life Sciences Stock Performance
The stock has a fifty day moving average of $0.06 and a 200-day moving average of $0.03. The company has a market cap of $7.56 million, a PE ratio of -0.43 and a beta of 0.28.
About StageZero Life Sciences
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.
Featured Stories
- Five stocks we like better than StageZero Life Sciences
- Breakout Stocks: What They Are and How to Identify Them
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is Insider Trading? What You Can Learn from Insider Trading
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Best Fintech Stocks for a Portfolio Boost
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
